Welcome to our dedicated page for Novavax news (Ticker: NVAX), a resource for investors and traders seeking the latest updates and insights on Novavax stock.
Novavax, Inc. (NASDAQ: NVAX) is a biotechnology company focused on vaccines, using a platform that combines protein-based nanoparticles with its proprietary Matrix-M® adjuvant. News about Novavax often centers on its COVID-19 vaccine Nuvaxovid™/Nuvaxovid®, its broader infectious disease pipeline, and the progress of key partnerships and collaborations.
Recent announcements highlight Novavax’s collaboration and license agreement with Sanofi, under which Sanofi has taken on lead commercial and regulatory responsibilities for Nuvaxovid in selected markets. News items cover marketing authorization transfers in the European Union and United States, milestone payments to Novavax, and Sanofi’s clinical data on combination vaccine candidates that incorporate Nuvaxovid and Matrix-M. Updates also describe regulatory approvals in markets such as Japan through partner Takeda, triggering additional milestone payments and royalty opportunities.
Investors following NVAX news will see regular coverage of quarterly financial results, revenue composition from product sales, supply sales and licensing and royalty streams, as well as information on Novavax’s site consolidation and cost footprint in Maryland. The company’s communications also describe early-stage research on vaccine candidates for shingles, Clostridioides difficile colitis and respiratory syncytial virus combinations, and the use of Matrix-M in the R21/Matrix-M malaria vaccine developed with Serum Institute of India and Oxford University.
This page aggregates press releases, conference participation announcements, regulatory updates and other material events related to Novavax. Readers can use it to monitor developments in the company’s vaccine programs, partnership milestones, capital structure transactions and strategic transformation as disclosed in public statements.
Novavax, Inc. (Nasdaq: NVAX) has completed its rolling submission to the Therapeutic Goods Administration (TGA) for provisional approval of its protein-based COVID-19 vaccine candidate, NVX-CoV2373, in Australia. This marks the first complete application for a protein-based COVID-19 vaccine in the country. The TGA submission includes data from pivotal Phase 3 trials, demonstrating efficacy rates of 96.4% against the original virus strain and 90.4% overall. Novavax plans further submissions in key markets, including the U.S., U.K., and Europe, with a goal to enhance global access to its vaccine.
Novavax, Inc. has completed its regulatory submission to the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) for its protein-based COVID-19 vaccine, NVX-CoV2373. This marks the first authorization submission for a protein-based COVID-19 vaccine in the U.K. The vaccine demonstrated high efficacy rates of 96.4% against the original virus and 89.7% overall in trials involving ~45,000 participants. Novavax plans to submit to additional global authorities, including the EU, Canada, and Australia, soon, with FDA submission expected by the end of 2021.
Novavax, Inc. (Nasdaq: NVAX) announces it will report its third quarter 2021 financial results on November 4, 2021, post-market close. The company will host a conference call at 4:30 p.m. EDT to discuss its operational highlights. Participants are encouraged to join early for a timely connection. A replay will be available from 7:30 p.m. EDT on the same day until November 11, 2021. Novavax focuses on developing innovative vaccines to combat serious infectious diseases, including COVID-19 and influenza.
Novavax, Inc. (Nasdaq: NVAX) announced that Dr. Vivek Shinde will present at the World Vaccine Congress Europe 2021 on October 20, 2021. The focus will be on the COVID-NanoFlu™ Combination Vaccine, a novel formulation that integrates the company's COVID-19 and NanoFlu™ vaccine candidates using the Matrix-M™ adjuvant.
The session is scheduled from 11:30 a.m. to 12:00 p.m. CET (5:30 a.m. to 6:00 a.m. EDT). For details, visit the Congress website.
On October 4, 2021, Novavax announced key leadership changes to strengthen its vaccine safety and clinical development teams. Dr. Denny Kim was appointed as Senior Vice President and Chief Safety Officer, with a focus on global vaccine safety. Other promotions include Dr. Raburn Mallory as Senior Vice President and Head of Clinical Development, and Dr. Marco Cacciuttolo as Senior Vice President of Process and Analytical Development. These appointments aim to enhance Novavax's capabilities as the company transitions to a commercial-stage organization, particularly in its pursuit of NVX-CoV2373, a COVID-19 vaccine.
On September 29, 2021, Novavax (Nasdaq: NVAX) announced its participation in the upcoming 2021 Maryland Life Sciences Bio Innovation Conference. The company will discuss its recombinant nanoparticle protein-based COVID-19 vaccine candidate, NVX-CoV2373, during a panel titled Health Equity and Vaccine Confidence. This panel is scheduled for October 4, 2021, from 1:00 to 1:50 p.m. EDT. Notable speakers include Lisa M. Dunkle, M.D. from Novavax, alongside other experts from the Department of Defense and the University of Maryland.
On September 23, 2021, Novavax hosted HM King Carl XVI Gustaf and HM Queen Silvia at its Uppsala facility to discuss the progress of NVX-CoV2373, its COVID-19 vaccine candidate. The visit highlighted Novavax's commitment to global vaccination efforts, with a focus on its patented Matrix-M™ adjuvant, enhancing immune response. NVX-CoV2373 has shown high efficacy in Phase 3 trials, including 100% efficacy against severe disease. Novavax is also advancing its NanoFlu™ vaccine and is committed to addressing urgent global health needs.
Novavax, Inc. (Nasdaq: NVAX) announced the publication of complete results from its pivotal Phase 3 trial of NanoFlu™, a recombinant quadrivalent seasonal influenza vaccine, in The Lancet Infectious Diseases. The trial demonstrated NanoFlu's enhanced immunogenicity and safety compared to a leading influenza vaccine in older adults. The vaccine achieved all primary endpoints, showing significantly improved immune responses, including a 22-66% increase in antibody responses. The findings support NanoFlu's potential efficacy, particularly amid ongoing evaluations for a combination COVID-19-influenza vaccine.
Novavax, Inc. (Nasdaq: NVAX) has submitted a regulatory application for emergency use listing of its recombinant nanoparticle protein-based COVID-19 vaccine to the World Health Organization (WHO) in collaboration with the Serum Institute of India. This submission aims to facilitate equitable vaccine distribution globally, particularly through the COVAX Facility. The vaccine demonstrated high efficacy in pivotal Phase 3 trials, achieving 100% protection against severe disease and 90.4% overall efficacy. The NVX-CoV2373 vaccine is designed to be easily stored and administered, reinforcing Novavax's commitment to combating the pandemic.
Novavax, Inc. (Nasdaq: NVAX) announced its participation in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on September 29, 2021, from 8:40 – 9:10 a.m. EDT. The discussion will feature the company's COVID-19 vaccine candidate, NVX-CoV2373. Key participants include Gregory M. Glenn, M.D., and John J. Trizzino. A replay of the session will be available on the company's website for 90 days. Novavax is advancing its developing vaccines, including NanoFlu™, which is set for regulatory submission.